Companies in #Hematologic Malignancies

ADC Therapeutics is a commercial-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. Its lead product Zynlonta (loncastuximab tesirine) is the first CD19-targeted ADC approved for relapsed/refractory diffuse large B-cell lymphoma. The company is advancing a pipeline of next-generation ADCs targeting both hematologic malignancies and selected solid tumors.

Allogene Therapeutics (NASDAQ: ALLO) is a clinical-stage biotechnology company headquartered in South San Francisco, California, pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease. Allogene's lead clinical programs include cemacabtagene ansegedleucel (cema-cel, ALLO-501A) for relapsed/refractory large B-cell lymphoma and the ALPHA3 trial of ALLO-329 (a CD19/CD70 dual-allogeneic CAR T) in autoimmune disease. The company was founded in 2017 by acquiring Pfizer's allogeneic CAR-T portfolio and is led by CEO Dr. Zach Roberts as of June 30, 2026.

MacroGenics is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-based therapeutics for cancer. Its proprietary DART and TRIDENT bispecific platforms enable multi-specific targeting, and the company has one approved HER2-targeted breast cancer drug, Margenza (margetuximab-cmkb).

TScan Therapeutics is a clinical-stage immunotherapy company developing a portfolio of TCR-T cell therapies for hematologic malignancies and solid tumors. The company's lead program TSC-101 is in the ALLOHA Phase 1 study for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, with positive initial data from Cohort C reported in 2026 showing 11 of 14 dosed patients achieving complete donor chimerism. TScan is preparing TSC-101 for a planned Phase 3 study in blood cancers as the next value-driving event. The company has also established a Cellares automated-manufacturing agreement for TSC-101 production scalability. TScan is headquartered in Waltham, Massachusetts and trades on the Nasdaq Capital Market under the symbol TCRX.

Tubulis is a biotechnology company developing a new generation of antibody-drug conjugates (ADCs) for the treatment of cancer. Its proprietary platforms — Tub-tag, P5 conjugation, and Topoisomerase-I inhibitor payloads — enable the design of highly stable, targeted ADCs with improved therapeutic index. In May 2026, Gilead Sciences completed the acquisition of Tubulis for up to $5 billion ($3.15B cash upfront + $1.85B milestones).